The islet's anti-hypoglycemia weapon: an endocrine cell of the pancreatic islets that releases glucagon when blood sugar falls, ordering the liver to pour glucose back into the blood; when its regulation fails, hyperglucagonemia helps drive diabetic hyperglycemia.
Under metabolic stress or beta cell injury, alpha cells can increase PC1/3 expression, switching proglucagon processing to yield GLP-1 and other peptides normally associated with intestinal L cells.
Alpha cells can potentially transdifferentiate into beta cells to replace lost beta-cell mass.
Physiological Role
Stimulated to produce glucagon by hypoglycemia, epinephrine, amino acids, other hormones and neurotransmitters — the counterweight to insulin in glucose homeostasis.
Glucagon binds receptors on hepatocyte plasma membranes, initiating glycogenolysis and signaling the liver to begin gluconeogenesis — the core of glycogen and gluconeogenic control.
Physiology extends beyond hepatic glucose output: glucagon carries critical roles regulating both lipid and amino acid metabolism.
Interactions
Oppose beta cells hormonally while depending on paracrine somatostatin braking from delta cells.
Act on hepatocytes, where glucagon receptor signaling raises blood glucose.
Clinical Relevance
High glucagon secretion is implicated in both type 1 and type 2 diabetes, and elevated plasma glucagon is considered an early sign of their development.
The glucagon response to hypoglycemia is completely absent in patients with type 1 diabetes — a dangerous loss of the rescue hormone.
Pharmacology now aims here from both directions: glucagon receptor antagonists to reduce glycemia in type 2 diabetes, glucagon receptor agonists for type 1 diabetes, and catabolic actions leveraged against obesity.